Oncology

Latest News

Tech Updates: McKesson Launches Precision Oncology Consortium; Financing for RISA Labs PA Platform

By Mary Caffrey

April 17th 2025

These advances are designed to improve uptake of biomarker-driven cancer care and reduce treatment delays.

Making Novel Cancer Therapies Available Requires Choices Because Resources Are Limited

By Kyle Munz

April 14th 2025

Businessman shows medical network wooden block for health, medicine, insurance, healthcare, care, concept. Medical technology services to solve public - ภัทรชัย รัตนชัยวงค์ - stock.adobe.com.jpeg

NCCN Data Find Racial, Socioeconomic Disparities in Quality of Care for Metastatic Pancreatic Cancer

By Giuliana Grossi

April 9th 2025

Comparing Breast Cancer Treatment Outcomes Between Fee-for-Service and Medicare Advantage

By Galen Shearn-Nance, BS
Rishi R. Sachdev, BS

April 4th 2025

Woman with keloid on shoulder | Image credit: weerajata – stock.adobe.com

Deep Learning Tool Differentiates Keloids From Malignant Lesions Without Dermoscopy

By Hayden E. Klein

April 2nd 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Watch Now

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

January 7th 2018

Combination Therapy May Benefit Subset of Patients With CLL Who Have Poor Response to Ibrutinib

AJMC Staff

A subset of patients with chronic lymphocytic leukemia (CLL) with highly expressed CD49d have poorer outcomes while on Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib, which antagonizes B-cell receptor (BCR) signals. However, a team of researchers may have found a way to treat these patients.

January 7th 2018

Dr Mark Fendrick on Indication-Based Drug Pricing in Cancer Care

The fact that you have certain drugs that treat numerous cancers, and that they may treat 1 cancer different or better than another, would suggest that we should probably have differential pricing models, said A. Mark Fendrick, MD, director of the Center for Value-Based Insurance Design at the University of Michigan.

January 6th 2018

Study Examines Cost-Effectiveness in Multiple Myeloma Treatments

Kaitlynn Ely

New drugs to treat multiple myeloma (MM) have provided clinical benefits, but a study published in the Journal of Managed Care & Specialty Pharmacy found not all of them can be considered cost effective.

January 6th 2018

Study Examines Cost-Effectiveness in Multiple Myeloma Treatments

Kaitlynn Ely

January 5th 2018

Patients With Small-Cell Lung Cancer Face Barriers to Combined-Modality Therapy

Jaime Rosenberg

While chemotherapy with thoracic radiation has been established as the standard of care for the initial treatment of non-metastatic small-cell lung cancer, a large proportion of patients do not receive these treatments and in turn have lower overall survival, according to a study published in JAMA Oncology.

January 5th 2018

AJMC® in the Press, January 5, 2018

AJMC Staff

Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.

January 5th 2018

Bo Gamble on COA's Role in 2018

Bo Gamble, director of Strategic Practice Initiatives at the Community Oncology Alliance (COA), believes that broadening communication and education is COA’s main goal in 2018.

January 4th 2018

Judy Berger on What Southwest Airlines Is Doing in Oncology

Southwest Airlines has set up a split fill program, pharmacy benefit manager, health advocacy program, and a cancer resource guide for employees, said Judy Berger, senior manager, benefits planning, Southwest Airlines.

January 4th 2018

Judge Dismisses Challenge to 340B Cuts, Final Rule Goes Into Effect

Jaime Rosenberg

A federal judge dismissed a move to block 340B cuts days before CMS’ final rule on it went into effect.

January 4th 2018

Higher Rates of Cardiovascular Adverse Events in Patients With MM Treated With Carfilzomib

Jaime Rosenberg

Carfilzomib was associated with higher rates of all-grade and high-grade cardiovascular adverse events (CVAE), and both later trial phase and higher doses of carfilzomib were associated with higher rates of CVAE, according to a study in JAMA Oncology.

January 3rd 2018

Terrill Jordan Discusses Making Refinements in Year 2 of OCM

Year 2 of the Oncology Care Model is about learning from the lessons of year 1 and extending implementation that has already been started, said Terrill Jordan, CEO of Regional Cancer Care Associates.

January 3rd 2018

Serum Protein Signature Predicts Survival in Patients With Melanoma Receiving Anti–PD-1 Therapy

Jaime Rosenberg

A pre-treatment signature of proteins used to predict survival in patients with metastatic melanoma receiving PD-1 inhibitors found that patients deemed sensitive by the test demonstrated significantly better overall survival.

January 1st 2018

How Value Frameworks Define Durable Survival of New Immuno-Oncology Agents

Laura Joszt, MA

New immuno-oncology agents are providing durable survival for some patients, but the cost of these treatments is very high, which is a cause for concern. In a new study in JAMA Oncology, researchers sought to assess how value frameworks defined the efficacy of new immuno-oncology agents.

December 31st 2017

Smokers Willing to Try E-Cigarettes More Successful at Smoking Less, Study Says

Allison Inserro

A small pilot study from the Hollings Cancer Center at the Medical University of South Carolina found that smokers who are willing to use e-cigarettes tend to smoke less and have increased quit attempts.

December 29th 2017

The Impact High OOP Costs Have on Patients Filling Prescriptions for Oral Cancer Drugs

Laura Joszt, MA

Patients with cancer may have more options for oral cancer medications, but high out-of-pocket costs still present a barrier to access, according to a new study in Journal of Clinical Oncology.

December 29th 2017

This Week in Managed Care: December 29, 2017

This week, the top managed care stories included a road map to develop state-level programs to care for complex populations; the Physician-focused Payment Technical Advisory Committee backed 2 new alternative payment models; a new cancer gene profiling test may open doors to new targeted therapies.

December 29th 2017

Top 2017 Articles in AJMC®'s Evidence-Based OncologyTM

Surabhi Dangi-Garimella, PhD

A look at the most popular articles published in Evidence-Based Oncology™ in 2017.

December 27th 2017

Dr Amy Abernethy Discusses Community Oncologists' Role in Modernizing Evidence Generation

Community oncologists have a major role in accelerating treatment development and providing them to patients, said Amy Abernethy, MD, PhD, the chief medical officer, chief scientific officer, and senior vice president of oncology at Flatiron Health.

December 27th 2017

Cancer Gene Profiling Test Can Open Doors to New Targeted Therapies

Jaime Rosenberg

While FoundationOne CDx, the comprehensive companion diagnostic test for solid tumors, gives patients the ability to be accurately matched with a targeted therapy, it also has potential benefits for patients with a less common types of cancers, said Stuart Goldberg, MD, chief scientific officer, Cota, in an interview with The American Journal of Managed Care®.

December 26th 2017

Sarah Cevallos: Physicians Need More Data to Determine if 2-Sided Risk is Appropriate

Until more data is available, it’s difficult for a practice or physician group to make an accurate assessment of whether or not 2-sided risk is appropriate, said Sarah Cevallos, chief revenue cycle officer, Florida Cancer Specialists. Physicians would need to see clear metrics in order to know if they will be achievable.

December 25th 2017

The Role of Oncologists in Moving to Value-Based Care: Torrie Fields Interviews Dr Michael Kolodziej

In this interview, recorded at the end of the first day of PCOC®, Torrie Fields, senior program manager at Blue Shield of California, and Michael Kolodziej, MD, of ADVI Health, discuss the move to value-based care in oncology, what practices need to do to be successful, and the role of team-based care.

December 25th 2017

Dr Shannon Maude Discusses Side Effects of CAR T Therapies

Most primary side effects of CAR T therapies occur early on after treatment and resolve quickly, but there are some that require long-term monitoring, explained Shannon L. Maude, MD, PhD, of The Children's Hospital of Philadelphia.

December 23rd 2017

Podcast: This Week in Managed Care—Individual Mandate Eliminated and Other Health News

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

December 23rd 2017

Dr Bobby Green on How Flatiron Is Working to Improve Care Delivery

Bobby Green, MD, MSCE, senior vice president of clinical oncology at Flatiron Health, discusses analyzing patient data to improve the overall care delivery and its challenges involved with being so early in the process.

December 22nd 2017

This Week in Managed Care: December 22, 2017

This week, the top managed care stories included the elimination of the Affordable Care Act's individual mandate; a new gene therapy for inherited vision loss that could cost $1 million; and a study found that social isolation can increase the risk of type 2 diabetes.

December 22nd 2017

Medical World News®, December 2017

AJMC Staff

Key drug approvals; alcohol cancer link.

December 22nd 2017

Articles That Gained the Most Traction on Facebook, Twitter, and LinkedIn in 2017

Jaime Rosenberg

Articles on type 2 diabetes management, colon cancer screenings, and anti-rheumatic drug approvals topped the list.

December 22nd 2017

Terrill Jordan: Year 1 Feedback on OCM

Based on CMMI's year 1 feedback on OCM, it is clear that a lot of planning is needed and education is crucial, said Terrill Jordan, CEO, of Regional Cancer Care Associates.

December 22nd 2017

5 Aspects of How Diet Does, and Does Not, Impact Health

Laura Joszt, MA

For the most part, it’s well known that eating healthy and in moderation is more beneficial to our health. In 2017, there were a number of news stories that drove that knowledge home.

December 21st 2017

FDA Grants Approval to Pertuzumab for Adjuvant Treatment in Patients With HER2-Positive Breast Cancer

Jaime Rosenberg

The FDA's 2013 accelerated approval of pertuzumab for neoadjuvant use was converted to full approval as part of treatment for patients with HER2-positive, locally advanced, inflammatory, or early-stage breast cancer.

...

57 58 59 60 61 62 63 64 65

...

184 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions